Avid­i­ty to seek ac­cel­er­at­ed ap­proval for FSHD drug; Ax­some to run an­oth­er tri­al

Plus, news about Mosan­na Ther­a­peu­tics, Con­cen­tra Bio­sciences, El­e­va­tion On­col­o­gy, Keros, TuHU­RA Bio­sciences and PolyPid:

Avid­i­ty Bio­sciences says FDA is open to ac­cel­er­at­ed ap­proval for FSHD …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER